BioCryst Pharmaceuticals
BCRX
#5073
Rank
NZ$2.76 B
Marketcap
NZ$13.14
Share price
-3.07%
Change (1 day)
0.80%
Change (1 year)

BioCryst Pharmaceuticals (BCRX) - Total debt

Total debt on the balance sheet as of September 2025 : NZ$1.11 Billion

According to BioCryst Pharmaceuticals 's latest financial reports the company's total debt is NZ$1.11 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

BioCryst Pharmaceuticals - Total debt on balance sheet (from 1996 to 2025)

Total debt by year

Year Total debt Change
2024-12-31NZ$1.43 B9.9%
2023-12-31NZ$1.30 B11.73%
2022-12-31NZ$1.16 B34.46%
2021-12-31NZ$0.86 B124.21%
2020-12-31NZ$0.38 B208.18%
2019-12-31NZ$0.12 B36.38%
2018-12-31NZ$92.16 M19.62%
2017-12-31NZ$77.05 M-0.65%
2016-12-31NZ$77.55 M75.89%
2015-12-31NZ$44.09 M15.16%
2014-12-31NZ$38.28 M4.88%
2013-12-31NZ$36.5 M0.11%
2012-12-31NZ$36.46 M-5.13%
2011-12-31NZ$38.43 M
2000-12-31NZ$0.02 M
1997-12-31NZ$0.17 M-59.42%
1996-12-31NZ$0.42 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
Repligen
RGEN
NZ$1.19 B 6.73%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
NZ$2.16 B 93.70%๐Ÿ‡บ๐Ÿ‡ธ USA
NanoViricides
NNVC
NZ$2.59 M-99.77%๐Ÿ‡บ๐Ÿ‡ธ USA
Novavax
NVAX
NZ$0.43 B-61.09%๐Ÿ‡บ๐Ÿ‡ธ USA
Gilead Sciences
GILD
NZ$43.17 B 3,764.29%๐Ÿ‡บ๐Ÿ‡ธ USA
Celldex Therapeutics
CLDX
NZ$4.53 M-99.59%๐Ÿ‡บ๐Ÿ‡ธ USA
GlaxoSmithKline
GSK
NZ$41.30 B 3,597.11%๐Ÿ‡ฌ๐Ÿ‡ง UK
Emergent BioSolutions
EBS
NZ$1.14 B 2.74%๐Ÿ‡บ๐Ÿ‡ธ USA
Cel-Sci
CVM
NZ$17.24 M-98.46%๐Ÿ‡บ๐Ÿ‡ธ USA